FIBRONET

STATISTICAL ANALYSIS PLAN

Version 1.4, 30/01/2018

Written by
Role: Biostatistician
Date
Signature

Reviewed by
Role: Data Management & Statistics Unit
Date
Signature

Boehringer Ingelheim
INDEX

LIST OF ABBREVIATIONS .............................................................................................................. 6
1 STATISTICAL ANALYSIS PLAN OBJECTIVES ........................................................................ 7
2 DEFINITION OF EVALUABLE PATIENTS ............................................................................. 8
3 COMPUTED VARIABLES .............................................................................................................. 10
4 CONTENTS ................................................................................................................................. 16

4.1 Patient disposition .................................................................................................................... 16
   Table 1. Enrolled and evaluable patients .................................................................................. 16
   Table 2. Reasons for non-eligibility to analyses ...................................................................... 16
   Table 3. Premature study termination ...................................................................................... 16
   Table 4. Months between baseline and follow up visits .......................................................... 16

4.2 Socio-demographics and clinical characteristics at enrollment ............................................. 17
   Table 5. Socio-demographic characteristics at enrollment ...................................................... 17

4.4 Primary objective: Clinical course of IPF during observation ............................................. 19
   Table 13. IPF symptoms ............................................................................................................. 19

4.6 Secondary objective #2: Frequency of exacerbations during observation .............................. 21
   Table 24. Exacerbations since IPF diagnosis ............................................................................. 21

4.7 Secondary objective #3: Health related quality of life (HRQoL) variation during 12 months of observation ................................................................. 22
   Table 26. EQ-5D-5L distribution of items of descriptive system and VAS during observation ........................................................................................................ 22
   Table 27. St.Georges Respiratory Questionnaire (SGRQ) ........................................................ 22

4.8 Secondary objective #4: Healthcare resource utilization from diagnosis up to the end of 12-month follow-up ................................................................. 22
   Table 28. Hospitalizations (inward/day hospital) and ICU admissions for IPF, IPF EXACERBATIONS OR IPF-RELATED ADVERSE EVENTS ......................................................................................... 22
   Table 29. Number of hospitalizations (inward/day hospital) and admissions to ICU and Overall duration of admission ............................................................................... 22
   Table 30. Emergency room accesses ...................................................................................... 22
   Table 31. Specialist and general practitioner outpatient visits ............................................... 22
   Table 32. Patients who performed laboratory tests ................................................................... 23
   Table 33. Laboratory tests: number and type ............................................................................ 23

4.9 Ongoing therapies for IPF ........................................................................................................ 23
   Table 34. IPF treatments ongoing at enrollment ...................................................................... 23
   Table 35. IPF treatments ongoing at 3-month follow up .......................................................... 23
   Table 36. IPF treatments ongoing at 6-month follow up .......................................................... 23

Table 20. Lung Function Assessments – Spirometry at each study visit and variation during observation period ................................................................................. 20
Table 21. Lung Function Assessments – Emogas analysis at each study visit and variation during observation period ................................................................................. 20
Table 22. Lung Function Assessments – 6-minute walked distance test at each study visit and variation during observation period ................................................................................. 21

Table 23. Hospitalizations (inward/day hospital) and ICU admissions for IPF, IPF EXACERBATIONS OR IPF-RELATED ADVERSE EVENTS ......................................................................................... 22
Table 24. Exacerbations since IPF diagnosis ............................................................................. 21
Table 25. St.Georges Respiratory Questionnaire (SGRQ) ........................................................ 22
Table 26. EQ-5D-5L distribution of items of descriptive system and VAS during observation ........................................................................................................ 22
Table 27. St.Georges Respiratory Questionnaire (SGRQ) ........................................................ 22
Table 28. Hospitalizations (inward/day hospital) and ICU admissions for IPF, IPF EXACERBATIONS OR IPF-RELATED ADVERSE EVENTS ......................................................................................... 22
Table 29. Number of hospitalizations (inward/day hospital) and admissions to ICU and Overall duration of admission ............................................................................... 22
Table 30. Emergency room accesses ...................................................................................... 22
Table 31. Specialist and general practitioner outpatient visits ............................................... 22
Table 32. Patients who performed laboratory tests ................................................................... 23
Table 33. Laboratory tests: number and type ............................................................................ 23
Table 34. IPF treatments ongoing at enrollment ...................................................................... 23
Table 35. IPF treatments ongoing at 3-month follow up .......................................................... 23
Table 36. IPF treatments ongoing at 6-month follow up .......................................................... 23
### 4.10 Ongoing pharmacological therapies for IPF

Table 37. IPF treatments ongoing at 12-month follow up

Table 38. Distribution of patients according to IPF pharmacological treatments ongoing at enrollment

Table 39. Distribution of patients according to IPF pharmacological treatments ongoing at 3-month follow up

Table 40. Distribution of patients according to IPF pharmacological treatments ongoing at 6-month follow-up visit

Table 41. Distribution of patients according to IPF pharmacological treatments ongoing at 12-month follow-up visit

Table 42. IPF pharmacological treatments from diagnosis to the end of observation period – Dosage regimen

Table 43. Time between diagnosis and start of therapy for IPF

### 4.11 Pharmacological therapies for IPF and exacerbations

Listing 44. Patients with exacerbations during observational period and therapy for IPF

### 4.12 Ongoing non pharmacological therapies for IPF

Table 45. IPF non pharmacological therapy ongoing at enrollment

Table 46. Distribution of patients according to IPF non pharmacological therapy ongoing at 3-month follow up

Table 47. Distribution of patients according to IPF non pharmacological therapy ongoing at 6-month follow-up visit

Table 48. Distribution of patients according to IPF non pharmacological therapy ongoing at 12-month follow-up visit

Table 49. IPF non pharmacological therapy from diagnosis to the end of observation period – Number of sessions of cardiopulmonary exercise training or psychological support

Table 50. Long term Oxygen therapy from diagnosis to the end of observation period – Dosage regimen

### 4.14 AEs and ADRs between diagnosis and end of observation

Table 52. Patients with AEs and ADRs between diagnosis and end of observation

Listing 53. AEs and ADRs between diagnosis and end of observation

### 4.15 Appendix

Table A3. Methods of diagnosis (by HRCT findings)

Table A4. IPF treatments ongoing at enrollment (Patients with IPF symptoms at baseline and no symptoms at 3-month follow up)

Table A5. Distribution of patients according to IPF pharmacological treatments ongoing at enrollment (Patients with IPF symptoms at baseline and no symptoms at 3-month follow up)

Table A6. IPF treatments ongoing at 3-month follow up (Patients with IPF symptoms at baseline and no symptoms at 3-month follow up)

Table A7. Distribution of patients according to IPF pharmacological treatments ongoing at 3-month follow up (Patients with IPF symptoms at baseline and no symptoms at 3-month follow up)
**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>ALAT</td>
<td>Latin American Thoracic Association</td>
</tr>
<tr>
<td>ATS</td>
<td>American Thoracic Society</td>
</tr>
<tr>
<td>BAL</td>
<td>BronchoAlveolar Lavage</td>
</tr>
<tr>
<td>BITSPA</td>
<td>Boehringer Ingelheim Italy S.p.A.</td>
</tr>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>BS</td>
<td>Biostatistician</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence Interval</td>
</tr>
<tr>
<td>CDM</td>
<td>Clinical Data Manager</td>
</tr>
<tr>
<td>CNS</td>
<td>Central Nervous System</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>DLCO</td>
<td>Diffusion Lung Capacity for carbon monoxide</td>
</tr>
<tr>
<td>eCRF</td>
<td>Electronic Case Report Form</td>
</tr>
<tr>
<td>EQ-5D-5L</td>
<td>EuroQol 5-dimension 5-level</td>
</tr>
<tr>
<td>ERS</td>
<td>European Respiratory Society</td>
</tr>
<tr>
<td>FVC</td>
<td>Forced vital capacity</td>
</tr>
<tr>
<td>FEV1</td>
<td>Forced expiratory volume in the 1st second</td>
</tr>
<tr>
<td>HRCT</td>
<td>High Resolution chest Computer Tomography</td>
</tr>
<tr>
<td>HRQoL</td>
<td>Health Related Quality of Life</td>
</tr>
<tr>
<td>ILD</td>
<td>Interstitial Lung Disease</td>
</tr>
<tr>
<td>INHS</td>
<td>Italian National Health Service</td>
</tr>
<tr>
<td>IPF</td>
<td>Idiopathic Pulmonary Fibrosis</td>
</tr>
<tr>
<td>JRS</td>
<td>Japanese Respiratory Society</td>
</tr>
<tr>
<td>LTOT</td>
<td>Long-Term Oxygen Therapy</td>
</tr>
<tr>
<td>LTx</td>
<td>Lung Transplantation</td>
</tr>
<tr>
<td>MAH</td>
<td>Market Authorization Holder</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Drug Regulatory Activities</td>
</tr>
<tr>
<td>Min</td>
<td>Minimum</td>
</tr>
<tr>
<td>MMF</td>
<td>Mycophenolate MoFetil</td>
</tr>
<tr>
<td>N</td>
<td>Number of observations</td>
</tr>
<tr>
<td>NIS</td>
<td>Non-interventional Study</td>
</tr>
<tr>
<td>p.o.</td>
<td>per os (oral)</td>
</tr>
<tr>
<td>PRO</td>
<td>Patient Related Outcomes</td>
</tr>
<tr>
<td>q.d.</td>
<td>quaque die (once a day)</td>
</tr>
<tr>
<td>QoL</td>
<td>Quality of Life</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>s.c.</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>SGRQ</td>
<td>St. George’s Hospital Respiratory Questionnaire</td>
</tr>
<tr>
<td>SD</td>
<td>Standard Deviation</td>
</tr>
<tr>
<td>t.i.d.</td>
<td>ter in die (3 times a day)</td>
</tr>
<tr>
<td>VC</td>
<td>Vital Capacity</td>
</tr>
<tr>
<td>TLC</td>
<td>Total Lung Capacity</td>
</tr>
<tr>
<td>UIP</td>
<td>Usual Interstitial Pneumonia</td>
</tr>
</tbody>
</table>
1 STATISTICAL ANALYSIS PLAN OBJECTIVES

The FIBRONET study is a multi-center, non-interventional (observational) prospective cohort study based mainly on newly collected data. A total of 200 consecutive patients will be enrolled in approximately 18 months (from the first patient enrolled). Patients will be followed-up for 1 year, with 3 intermediate evaluations after 3 (±1), 6 (±1) and 9 (±1) months since baseline (which is compatible with current clinical practice in Italy for IPF patients management).

The present Statistical Analysis Plan has been designed considering the following input documents: the Study Protocol v.1.0 26/06/2015 and the electronic case report form v. 1.1.1 30/11/2015.

This SAP is aimed at evaluating the following study objectives:

**Primary objective:**
1. In a sample of IPF diagnosed patients to describe the clinical course during 12 months of observation, in terms of:
   - IPF symptoms
   - lung function (VC, FVC, FEV1, TLC, DLCO, pO2, pCO2; SaO2, PaO2 and PaCO2 at rest)
   - exercise tolerance (6-minute walk distance test)

**Secondary objectives:**
1. Description of characteristics of IPF patients at enrollment in terms of:
   - key (socio-) demographic data
   - IPF risk factors, comorbidities
   - IPF disease severity and manifestation (including lung function, cardiopulmonary exercise testing and/or exercise capacity if available, laboratory values)
   - Methods used for IPF diagnosis
   - IPF treatment modalities (detailed information on prescribed drugs and dose; non-pharmacological treatment; lung transplantation)
2. To describe the frequency of exacerbations during 12 months of observation.
3. To describe HRQoL variation, measured with SGRQ, EuroQol (EQ) 5-dimension 5-level (EQ-5D-5L) descriptive system and EQ VAS, during 12 months of observation.
4. To describe health care sector-related costs from diagnosis up to the end of 12-month follow-up according to the Italian National Health Service (INHS) point of view.

The ongoing (pharmacological and non-pharmacological) therapies at each follow up will be described too.

In this document the eCRF fields are indicated as follows: “label of the field” [name of the eCRF form.name of the variable in the dataset].
2 DEFINITION OF EVALUABLE PATIENTS

All enrolled patients fulfilling the following criteria will be considered evaluable for the evaluation of FIBRONET primary study objective:

2.1 Patients evaluable at enrollment

All enrolled patients meeting the following inclusion and exclusion criteria will be considered evaluable at enrollment:

1. Patient aged>=40 years
   - Question “1. Patient aged>=40 years” = “Yes” [F01_INC_EXC_CRITERIA.CI_1]
   AND
   - Age at enrollment visit (years) ≥ 40 [._PatientInfo.Age]
   AND
   1. Patients aged >= 40 years [F27_PROTOCOL_DEVIATION_FORM.PD_CI_1] not checked

2. Written informed consent to both participation in the study and privacy
   - Question “2. Written informed consent to both participation in the study and privacy” = “Yes” [F01_INC_EXC_CRITERIA.CI_2]
   AND
   - Date of informed consent signature (dd/mm/yyyy) not missing [._PatientInfo.Date_CI]
   AND
   - Date of privacy form signature (dd/mm/yyyy) not missing [._PatientInfo.Date_privacy]
   AND
   - Date of informed consent signature (dd/mm/yyyy) ≤ Date of enrollment visit (dd/mm/yyyy)
   AND
   - Date of privacy form signature (dd/mm/yyyy) ≤ Date of enrollment visit (dd/mm/yyyy)
   AND
   - 2. Written informed consent to both participation in the study and privacy [F27_PROTOCOL_DEVIATION_FORM.PD_CI_2] not checked

3. Physician diagnosed IPF during the last 3 months based upon recent ATS/ERS/JRS/ALAT guidelines 2011 (see Tables A1-A2 of study protocol - Annex 1):
   - Exclusion of other known causes of ILD (e.g. domestic and occupational environmental exposures, connective tissue disease and drug toxicity)
   - Assessment of IPF based on HRCT or HRCT and surgical lung biopsy* if available.

   Question “3. Physician diagnosed IPF during the last 3 months based upon recent ATS/ERS/JRS/ALAT guidelines 2011” = “Yes” [F01_INC_EXC_CRITERIA.CI_3]
   AND
   - Date of first IPF diagnosis (mm/yyyy) not missing or NK [F05_DIAGNOSIS_IPF.Dia_Date_IPF_Diagnosis]
   AND
   - round ((Date_enrollment* - Date of first IPF diagnosis)/30.4375) ≤ 3
   AND
   - Date of first IPF diagnosis (mm/yyyy) ≤ Date of enrollment visit (dd/mm/yyyy)
   AND
   - IPF diagnosis based on [F05_DIAGNOSIS_IPF.Dia_IPF_diagnosis_based_on, DIA_IPF_based_on_other] must include the following options: “HRCT” or (“HRCT” and “Surgical lung biopsy”).
   AND
   - 3. Physician diagnosed IPF during the last 3 months based upon recent ATS/ERS/JRS/ALAT guidelines 2011 (see Tables A1-A2 for HRCT and histology criteria) [F27_PROTOCOL_DEVIATION_FORM.PD_CI_3] not checked

   In case of missing month or day in date of first IPF diagnosis they will be considered respectively =01 and =July.

   *It will be recalculated considering for all patients day=01.

---

1 The number of patients evaluable for analyses will be previously shared with sponsor for approval before first release of statistical report.
4. Patient with further follow-up possible with enrolling investigator during planned study period

- Question “4. Patient with further follow-up possible with enrolling investigator during planned study period” = “Yes” [F01_INC_EXC_CRITERIA.CI_4]
  
- 4. Patient with further follow-up possible with enrolling investigator during planned study period [F27_PROTOCOL_DEVIATION_FORM.PD_CI_4] not checked

5. Patient capable of discernment and able to read or write in Italian language

- Question “5. Patient capable of discernment and able to read or write in Italian language” = “Yes” [F01_INC_EXC_CRITERIA.CI_5]
  
- 5. Patients capable of discernment and able to read or write in Italian language. [F27_PROTOCOL_DEVIATION_FORM.PD_CI_5] not checked

6. Patient not included in clinical trials or other IPF/ILD registries

- Question “6. Inclusion in clinical trials or other IPF/ILD registries” = “No” [F01_INC_EXC_CRITERIA.EC_1]
  
- 1. Inclusion in clinical trials or other IPF/ILD registries [F27_PROTOCOL_DEVIATION_FORM.PD_EC_1] not checked

7. Patient without lung transplantation expected within the next 6 months

- Question “7. Lung transplantation expected within the next 6 months” = “No” [F01_INC_EXC_CRITERIA.EC_2]
  
- 2. Lung transplantation expected within the next 6 months [F27_PROTOCOL_DEVIATION_FORM.PD_EC_2] not checked

8. Female patient not pregnant at enrollment or breast feeding

- Question “8. Pregnancy or breast feeding” = “No” [F01_INC_EXC_CRITERIA.EC_3]
  
- 3. Pregnancy or breast feeding [F27_PROTOCOL_DEVIATION_FORM.PD_EC_3] not checked

9. Male and female patients

- Gender at enrollment visit [PatientInfo.Gender] not missing

10. Available evaluation of at least one of the following at enrollment:

- IPF symptoms
  
  - IPF symptoms at study visit? [F06_IPF_SYMPTOMS.SYM_IPF_symptoms_YN] = Yes and at least one symptom [F06_IPF_SYMPTOMS.SYM_IPF_symptoms, SYM_IPF_symptoms_other] not missing OR IPF symptoms at study visit? = No OR mMRC dyspnea score [F15_MMRC.MMRC] not missing.

- Lung function (VC, FVC, FEV1, TLC, DLCO, pO2, pCO2; SaO2, PaO2 and PaCO2 at rest)
  
  - [F07_LUNG_FUNCTION_ASS. LU_Spirometry_YN] = Yes and at least one parameter [F07_LUNG_FUNCTION_ASS. LU_FEV1,-- LU_saO2_Num] not missing.
  
  - [F07_LUNG_FUNCTION_ASS. LU_Emogas_YN] = Yes and at least one parameter [F07_LUNG_FUNCTION_ASS. LU_PO2_Num, LU_PaO2_Num, LU_PCO2_Num, LU_PaCO2_Num] not missing.

- Exercise tolerance (6-minute walk distance test)
  
  - [F07_LUNG_FUNCTION_ASS. LU_6_Minute_YN] = Yes and 6-minute walked distance (m) [F07_LUNG_FUNCTION_ASS. LU_6_minute_distance_Num] not missing.
3 COMPUTED VARIABLES

The following variables will be computed as described below.

BMI
BMI index will be computed as follows: Weight (Kg) $\frac{\text{[F02_SOCIO_DEMOGRAPHICS.SD_Weight_Num]}}{(\text{Height (cm)} \times 100)^2}$


Smoking duration at enrolment (years)
- For patient who are current smokers by the time of enrolment ([F03_IPF_RISK_FACTORS.RF_smoking] = “Current smoker”):
  Smoking duration at enrolment = YEAR (Date of enrolment visit [PatientInfo.Date_enrollment]) – Start year [F03_IPF_RISK_FACTORS.RF_start_year]), if Start year and Date of enrolment visit are not missing.
- For patient who are former smokers by the time of enrolment ([F03_IPF_RISK_FACTORS.RF_smoking] = “Former smoker”):
  Smoking duration at enrolment = Stop year [F03_IPF_RISK_FACTORS.RF_stop_year] – Start year [F03_IPF_RISK_FACTORS.RF_start_year]), if Stop year and Start year are not missing.

Comorbidities at enrollment
The comorbidities in class other [F04_COMORBIDITIES.COM_Comorbidities_other] will be translated into English and typos will be corrected. Moreover, CDM will recode them into the classes of field Comorbidity [F04_COMORBIDITIES.COM_Comorbidities] (Atherothrombotic disease including coronary heart disease, Cerebrovascular disease, etc.), if necessary.

The patients with Comorbidity [F04_COMORBIDITIES.COM_Comorbidities]=Other and [F04_COMORBIDITIES.COM_Comorbidities_other] = BENIGN PROSTATIC HYPERTROPHY or HYPERCHOLESTEROLEMIA will be considered with Comorbidity [F04_COMORBIDITIES.COM_Comorbidities]= Benign Prostatic Hypertrophy or Hypercholesterolemia.

Methods of diagnosis (other)
The following self-evident corrections will be applied:
- If IPF diagnosis based on other test, specify [F05_DIAGNOSIS_IPF.DIA_IPF_based_on_other] = “CT with contrast medium on Ago 2015 (no UIP); PET in Sep 2015 (possible Intersitial disease)” then DIA_IPF_diagnosis_based_on_other = “CT;PET”;
- if DIA_IPF_diagnosis_based_on_other = ‘Bioumoral examination for autoimmunity exclusion’ or ‘biopsy salivary gland for autoimmunity exclusion’ then DIA_IPF_diagnosis_based_on_other = “TEST FOR AUTOIMMUNITY EXCLUSION”.

Patient who performed V2 (3-months), V3 (6-months), V4 (9-months), V5 (12-months) follow up visit
At each follow up visit they will be defined as patients satisfying the following criteria:

1. Patients evaluable at enrollment (i.e., responding to criteria of par 2.1 Patients evaluable at enrollment)
2. Data collected at x-month follow-up = “Yes” [F16_PATIENT_DISPOSITION, 3 month f-up.PD_1; 6 month f-up.PD_1; 9 month f-up.PD_1; 12 month f-up.PD_1]
   where x=3, 6, 9, 12-

3. Follow-up performed at x ±1.5 months from enrollment (where x=3, 6, 9, 12-)
   – (Date of follow up visit (dd/mmm/yyyy) [F16_PATIENT_DISPOSITION, 3 month f-up.PD_2; 6 month f-up.PD_2; 9 month f-up.PD_2; 12 month f-up.PD_2]– Date of enrolment visit (dd/mmm/yyyy) [_PatientInfo. Date_enrollment]/30.4375 ≥ 1.5 (or 4.5 or 7.5 or 10.5))
   AND
   – (Date of follow up visit (dd/mmm/yyyy) [F16_PATIENT_DISPOSITION, 3 month f-up.PD_2]– Date of enrolment visit (dd/mmm/yyyy) [_PatientInfo. Date_enrollment]/30.4375 ≤ 4.5 (or 7.5 or 10.5 or 13.5))

4. With available IPF symptoms evaluation at baseline and at x ±1.5 months from enrollment (where x=3, 6, 9, 12-)
   – (IPF symptoms at baseline ? [F06_IPF_SYMPTOMS.SYM_IPF_symptoms_YN]=No OR (IPF symptoms at baseline?=Yes AND at least one symptom [F06_IPF_SYMPTOMS.SYM_IPF_symptoms, SYM_IPF_symptoms_other] not missing))
   AND
   – (IPF symptoms at x-month follow up? [F06_IPF_SYMPTOMS.SYM_IPF_symptoms_YN]=No OR (IPF symptoms at x-month follow up?=Yes AND at least one symptom [F06_IPF_SYMPTOMS.SYM_IPF_symptoms, SYM_IPF_symptoms_other] not missing)
   where x=3, 6, 9, 12-

IPF symptoms
For patients with if other symptom, specify [F06_IPF_SYMPTOMS.SYM_IPF_symptoms, SYM_IPF_symptoms_other] = EXERTIONAL DYSPNEA or DISABLING DYSPNEA the field will be considered as DYSPNEA.

Incident IPF symptom at x-month follow up
IPF symptom absent at enrollment visit and present at x-month follow-up visit) [F06_IPF_SYMPTOMS.SYM_IPF_symptoms]
Where x=3, 6, 9, 12-

Patients with incident IPF symptom at x-month follow up
Patients with incident IPF symptom (according to previous definition) over total number of patients without symptom at baseline.
Where x=3, 6, 9, 12-

Remitted IPF symptom at x-month follow up
IPF symptom present at enrollment visit and absent at x-month follow-up visit) [F06_IPF_SYMPTOMS.SYM_IPF_symptoms]
Where x=3, 6, 9, 12-

Patients with remitted IPF symptom at x-month follow up
Patients with remitted IPF symptom (according to previous definition) over total number of patients with symptom at baseline.
Where x=3, 6, 9, 12-
Lung function assessment

For a patient with FEV1 (L)=170 at baseline and for a patient with FVC (L)=1330 at 3-month follow up the values will be set to missing. Values of DLCO with unit [F07_LUNG_FUNCTION_ASS.LU_DLCO_unit]=ml/min/mmHg will be converted to mmol/min/kPa according to the following formula: DLCO (mmol/min/kPa)=DLCO (ml/min/mmHg)/2.986 (reference: Diffusing Capacity: How to get it right Jensen R and Crapo RO Respir Care 2003: 48 (8): 777-782).

At each follow up visits the absolute changes of lung function assessments vs baseline values will be calculated as:

\[
\text{Change}_{x} = \text{value of parameter } x \text{ at follow up visit} - \text{value of parameter } x \text{ at baseline visit}
\]

Where \( x = \) FEV1, FEV1 of the predicted, FVC, FVC of the predicted, FEV1/FVC, VCl, RV, TLC, DLCO, DLCO of the predicted, SaO2 and all parameters of emogas analysis and \( i = \) follow up at 3, 6, 9, 12 months.

The relative change of FVC of the predicted (%) will be calculated as:

\[
\text{Change of FVC of the predicted (%)} = \frac{\text{value of FVC of the predicted (%) at follow up visit} - \text{value of FVC of the predicted (%) at baseline visit}}{\text{value of FVC of the predicted (%) at baseline visit}} \times 100.
\]

Where \( i = \) follow up at 3, 6, 9, 12 months.

The following classes will be considered for the relative change of FVC of the predicted (as described above) between baseline and follow up:

\(<5\%; 5-10\%; >10\%\).

Patient with at least one exacerbation since IPF diagnosis till end of observation period

The proportion of patients with at least one exacerbation during observation period will be computed as the ratio between the number of patients with one or more episodes of exacerbation occurred since IPF diagnosis till end of observation period over the total number of evaluable patients. Patients who drop-out without having exacerbations before the end of the study, will be considered in the denominator of the proportion of interest.

An exacerbation will be considered occurred during observation period if onset date \([F08_EXACERBATIONS.Ex_Exacer_1_Ons_date-Ex_Exacer_10_Ons_date]\) >= date of first IPF diagnosis (mm/yyyy) \([F05_DIAGNOSIS_IPF.DIA_Date_IPF_diagnosis]\) and onset date \([F08_EXACERBATIONS.Ex_Exacer_1_Ons_date-Ex_Exacer_10_Ons_date]\) <= last available visit date \([P16_PATIENT_DISPOSITION.PD_2]\) (for patients who completed the study \([F19_STUDY_COMPLETION.SC_1]\) = Yes) OR date of Date of drop out or death \([F19_STUDY_COMPLETION.SC_4, SC_5]\) (for patients who did not complete the study \([F19_STUDY_COMPLETION.SC_1]\) = No).

Health Related Quality of Life (HRQoL) EQ-5D-5L (see Appendix 8.3)

The EQ-5D-5L is a standardized measure of health status, it is filled in by patients. It consists of 2 sections: “EQ-5D descriptive system” and EQ visual analogue scale (EQ VAS).

The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ VAS indicate the health status self-assessed by the patient on a visual analogue scale from 0 to 100, where 100 is the “best imaginable health state” and 0 the “worst imaginable health state”. It can be used as a quantitative measure of health as judged by respondents.

**St. George’s Respiratory Questionnaire (SGRQ)** (see Appendix 8.5)

The SGRQ is designed to measure health impairment in patients with asthma and COPD. There is a report of its validation in a small study of adults with cystic fibrosis (Archivos de Bronconeumologia Volume 43, Issue 4, April 2007, pages 205-211). It is in two parts. Part I produces the Symptoms score, and Part 2 the Activity and Impacts scores. A Total score is also produced.

**Part 1 (Questions 1-8)** addresses the frequency of respiratory symptoms. It is not designed to be a precise epidemiological tool, but to assess the patient’s perception of their recent respiratory problems.

**Part 2 (Sections 9-17)** addresses the patient’s current state (i.e. how they are these days).

The Activity score measures disturbances to daily physical activity. The Impacts score covers a range of disturbances of psycho-social function. Validation studies for the original SGRQ showed that this component relates in part to respiratory symptoms, but it also correlates quite strongly with exercise performance (6-minute walking test), breathlessness in daily life (MRC breathlessness score) and disturbances of mood (anxiety and depression). The Impacts score is, therefore, the broadest component of the questionnaires, covering the whole range of disturbances that respiratory patients experience in their lives.

Three component scores are calculated: Symptoms; Activity; Impacts

One Total score is also calculated.

**PRINCIPLE OF CALCULATION**

Each questionnaire response has a unique empirically derived ‘weight’. The lowest possible weight is zero and the highest is 100.

Each component of the questionnaire is scored separately in three steps:

i. The weights for all items with a positive responses are summed.

ii. The weights for missed items are deducted from the maximum possible weight for each component. The weights for all missed items are deducted from the maximum possible weight for the Total score.

iii. The score is calculated by dividing the summed weights by the adjusted maximum possible weight for that component and expressing the result as a percentage:

\[
\text{Score} = \frac{100 \times \text{Summed weights from positive items in that component}}{\text{Sum of weights for all items in that component}}
\]

The Total score is calculated in similar way:

\[
\text{Score} = \frac{100 \times \text{Summed weights from positive items in the questionnaire}}{\text{Sum of weights for all items in the questionnaire}}
\]

**IPF pharmacological treatments ongoing at enrollment**

All IPF pharmacological treatments having (Start date of therapy (dd/mmm/yyyy) [F23.IPFPHARMACOLOGICAL.THERAPY.START_DATE.THER] >= date of first IPF diagnosis (mm/yyyy) [F05_DIAGNOSIS.IPF.DIA_Date.IPF_diagnosis] AND Start date of therapy (dd/mmm/yyyy) < Date of enrollment visit AND (end date (dd/mmm/yyyy) [F23.IPFPHARMACOLOGICAL.THERAPY.END_DATE.THER] > Date of enrollment visit (dd/mmm/yyyy) [PatientInfo.Date_enrollment] OR (end date missing AND “Ongoing at the end of observation?” = “Yes”)) will be considered.

Drug names will be coded by CDM in actives.

**IPF pharmacological treatments ongoing at 3, 6 and 12-month follow-up visit**

All IPF pharmacological treatments having (start date [F23.IPFPHARMACOLOGICAL.THERAPY.START_DATE.THER] >= date of first IPF diagnosis (mm/yyyy) [F05_DIAGNOSIS.IPF.DIA_Date.IPF_diagnosis] AND < date of follow-up visit) AND ((end date [F23.IPFPHARMACOLOGICAL.THERAPY.END_DATE.THER] >= date of first IPF diagnosis (mm/yyyy) [F05_DIAGNOSIS.IPF.DIA_Date.IPF_diagnosis] AND end date > date of follow-up visit [F16.PATIENT_DISPOSITION_PD.2] OR (end date = missing and “Ongoing at the end of observation?” = “Yes” [F23.IPFPHARMACOLOGICAL.THERAPY.ONGOING_THER])) will be selected.
IPF non-pharmacological therapy ongoing at enrollment
IPF non pharmacological treatments from diagnosis and ongoing at enrollment will be defined as follows.
All IPF non-pharmacological therapy having Start date of therapy (dd/mmm/yyyy) [F24_NON_PHARMACOLOGICAL_THERAPY.START_DATE_NF] >= date of first IPF diagnosis (mm/yyyy) [F05_DIAGNOSIS_IPF.DIA_Date_IPF_diagnosis] AND Start date of therapy (dd/mmm/yyyy) < Date of enrollment visit AND (end date (dd/mmm/yyyy) [F24_NON_PHARMACOLOGICAL_THERAPY.END_DATE_NF] > Date of enrollment visit (dd/mmm/yyyy) [.PatientInfo.Date_enrollment]) OR (missing and “Ongoing at the end of observation?” [F24_NON_PHARMACOLOGICAL_THERAPY.ONGOING_NF_THER] = “Yes”) will be considered.
For patients receiving more than one therapy, combination of therapies will be reported (e.g. Long-term oxygen therapy + Cardiopulmonary exercise training).

IPF non pharmacological treatments ongoing at 3-, 6- and 12-month follow-up visit
IPF non pharmacological treatments from diagnosis and ongoing at 3-, 6- or 12-month follow up will be defined as follows.
At each follow-up visit all treatments having (start date [F24_NON_PHARMACOLOGICAL_THERAPY.START_DATE_NF] >= date of first IPF diagnosis (mm/yyyy) [F05_DIAGNOSIS_IPF.DIA_Date_IPF_diagnosis] AND < date of follow-up visit ) AND
((end date [F24_NON_PHARMACOLOGICAL_THERAPY.END_DATE_NF] >= date of first IPF diagnosis (mm/yyyy) [F05_DIAGNOSIS_IPF.DIA_Date_IPF_diagnosis] AND end date > date of follow-up visit [F16_PATIENT_DISPOSITION.PD_2] OR (end date = missing and “Ongoing at the end of observation?” = “Yes”) [F24_NON_PHARMACOLOGICAL_THERAPY.ONGOING_NF_THER]) will be selected.
Patients with AEs or ADRs during observation period
Are defined as patients with at least one AEs or ADRs between diagnosis and end of observation defined as events with date of diagnosis <= start date AE <= date of last available follow up.
4 CONTENTS

The tables to be produced for interim report are in green (if analysis of follow up data is planned, data collected up to 3-month follow up will be considered).

Missing data will not be imputed and so patients with missing data will be excluded from the analyses of that variable(s).

If the investigator is unable to collect the requested information the data will be “NK” (Not Known) or “NA” (Not Available), if the investigator did not record the information the data will be “Not Recorded”.

4.1 Patient disposition

Table 1. Enrolled and evaluable patients

The table will provide absolute and relative frequencies of:

- patients enrolled in the FIBRONET study
- patients evaluable at enrollment (as described in par. 2.1)
- patients who performed V2 (3 ± 1.5 months)
- patients who performed V3 (6 ± 1.5 months)
- patients who performed V4 (9 ± 1.5 months)
- patients who performed V5 (12 ± 1.5 months)

The percentages will be computed over the total number of enrolled patients.

Table 2. Reasons for non-eligibility to analyses

The table will describe the reasons for patient non-eligibility at enrollment.

Absolute and relative frequency distribution will be performed; the percentages will be computed out of the total number of enrolled patients.

Table 3. Premature study termination

The table will describe the distribution of patients withdrawn from the study (“Did the patient complete the study?” [F19_STUDY_COMPLETION.SC_1] = “No”) and the reasons for premature study termination (“Cause of drop out” [F19_STUDY_COMPLETION.SC_2]).

Absolute and relative frequency distribution will be performed; as for withdrawal, percentages will be computed out of the total number of patients evaluable at enrollment.

As regards reasons of withdrawal, the percentages will be computed out of the total number of patients withdrawn from the study. A patient could withdraw from the study for more than one reason.

The distribution of patients withdrawn for other reasons will be also reported in a separate table (“If other cause, specify:” ≠ missing [F19_STUDY_COMPLETION.SC_3]), if other reason frequency will be >20%.

Table 4. Months between baseline and follow up visits

The table will provide main descriptive statistics (mean, median, standard deviation, quartiles, min, max) of time (months) between baseline and each follow up visit.

Patients who performed each follow up visit will be considered.
4.2 Socio-demographics and clinical characteristics at enrollment

Table 5. Socio-demographic characteristics at enrollment
The table will provide:

- Main descriptive statistics (mean, median, standard deviation, quartiles, min, max) of patients’ Age at enrollment ([PatientInfo.Age])
- Patient distribution by Gender ([PatientInfo.Gender])
- Patient distribution by Race ([F02_SOCIO_DEMOGRAPHICS.SD_Race])
- Patient distribution by Highest education level at baseline ([F02_SOCIO_DEMOGRAPHICS.SD_Education])
- Patient distribution by Employment status at baseline ([F02_SOCIO_DEMOGRAPHICS.SD_Employment])

Statistics will be computed out of the total number of patients evaluable at enrollment.
4.4 Primary objective: Clinical course of IPF during observation

Table 13. IPF symptoms

The table will provide at enrollment and at V2, V3, V4, V5:

- Frequency distribution of patients with at least one IPF symptom [F06_IPF_SYMPTOMS.SYM_IPF_symptoms_YN]
- Frequency distribution of IPF symptoms [F06_IPF_SYMPTOMS.SYM_IPF_symptoms]

Descriptives will be computed out of the total number of patients who performed the specific visit.
Table 20. Lung Function Assessments – Spirometry at each study visit and variation during observation period

The table will provide at enrollment, V2, V3, V4, V5 main descriptive statistics (mean, median, standard deviation, quartiles, min, max) of:

- FEV1 (L) \([F07\_LUNG\_FUNCTION\_ASS.LU\_FEV1]\)
- FEV1 of the predicted (%) \([F07\_LUNG\_FUNCTION\_ASS.LU\_FEV1\_predicted]\)
- FVC (L) \([F07\_LUNG\_FUNCTION\_ASS.LU\_FVC]\)
- FVC of the predicted (%)
- FEV1/FVC (%) \([F07\_LUNG\_FUNCTION\_ASS.LU\_FEV1\_FVC]\)

- Total lung capacity (L) \([F07\_LUNG\_FUNCTION\_ASS.LU\_TLC\_Num]\)
- DLCO \([F07\_LUNG\_FUNCTION\_ASS.LU\_DLCO\_Num]\), along with the respective DLCO unit \([F07\_LUNG\_FUNCTION\_ASS.LU\_DLCO\_unit]\).
- DLCO of the predicted (%) \([F07\_LUNG\_FUNCTION\_ASS.LU\_DLCO\_Predicted\_Num]\)
- SaO2 (%) \([F07\_LUNG\_FUNCTION\_ASS.LU\_SAO2\_Num]\)
- change at each follow-up visit vs baseline of FEV1 (L)
- change at each follow-up visit vs baseline of FEV1 of the predicted (%)
- change at each follow-up visit vs baseline of FVC (L)
- (absolute and relative) change at each follow-up visit vs baseline of FVC of the predicted (%)
- change at each follow-up visit vs baseline of FEV1/FVC (%)

- change at each follow-up visit vs baseline of Total lung capacity (L)
- change at each follow-up visit vs baseline of DLCO, along with the respective DLCO unit
- change at each follow-up visit vs baseline of DLCO of the predicted (%)
- change at each follow-up visit vs baseline of SaO2 (%)

Evaluable patients at the specific visit with spirometry performed \([F07\_LUNG\_FUNCTION\_ASS.LU\_spirometry\_YN]\) at study visit or in the previous 3 months will be considered.

Table 21. Lung Function Assessments – Emogas analysis at each study visit and variation during observation period

The table will provide at enrollment, V2, V3, V4, V5 the main descriptive statistics (mean, median, standard deviation, quartiles, min, max) of:

- PO2 (mmHg) \([F07\_LUNG\_FUNCTION\_ASS.LU\_PO2\_Num]\)
- PaO2 (mmHg) \([F07\_LUNG\_FUNCTION\_ASS.LU\_PaO2\_Num]\)
- PCO2 (mmHg) \([F07\_LUNG\_FUNCTION\_ASS.LU\_PCO2\_Num]\)
- PaCO2 (mmHg) \([F07\_LUNG\_FUNCTION\_ASS.LU\_PaCO2\_Num]\)
- change at each follow-up visit vs baseline of PO2 (mmHg)
- change at each follow-up visit vs baseline of PaO2 (mmHg)
- change at each follow-up visit vs baseline of PCO2 (mmHg)
- change at each follow-up visit vs baseline of PaCO2 (mmHg)

Evaluable patients at the specific visit with emogas analysis performed \([F07\_LUNG\_FUNCTION\_ASS.LU\_emogas\_YN]\) at study visit or in the previous 3 months will be considered.
Table 22. Lung Function Assessments – 6-minute walked distance test at each study visit and variation during observation period
The table will provide at enrollment, V2, V3, V4, V5 the main descriptive statistics (mean, median, standard deviation, quartiles, min, max) of:
- Start SpO2 (%)[F07_LUNG_FUNCTION_ASS.START_SPO2_Num]
- 6-minute walked distance (m)[F07_LUNG_FUNCTION_ASS.LU_6_minute_distance_Num]
- SpO2 at the end of the test (%)[F07_LUNG_FUNCTION_ASS.END_SpO2_Num]
- test duration [F07_LUNG_FUNCTION_ASS.LU_Time_stopped_Min, LU_Time_stopped_Sec]. Minutest and seconds fields will be merged, and test duration will be expressed in minutes (seconds will be divided by 60).
- change in 6 minute walked distance test duration at each follow-up visit vs baseline. Minutes and seconds fields will be merged, and test duration will be expressed in minutes (seconds will be divided by 60).

The table will be provided overall and stratified by patients with test performed with O2 and without O2 [F07_LUNG_FUNCTION_ASS.LU_6_minute_test].

Evaluable patients at the specific visit with test performed [F07_LUNG_FUNCTION_ASS.LU_6_minute_YN] at study visit or in the previous 3 months will be considered.

4.6 Secondary objective #2: Frequency of exacerbations during observation

Table 24. Exacerbations since IPF diagnosis
This table will describe the absolute and relative frequency distribution of patients with:
- at least one exacerbation during observation period since IPF diagnosis [F08_EXACERBATIONS.EX_Exacerbation_YN]
- at least one mild, moderate, severe exacerbation during observation period since IPF diagnosis
[F08_EXACERBATIONS.Ex_exacer_1-10_Severity]

Percentages will be computed out of the total number of patients evaluable at enrollment.

The table will provide the descriptive statistics (mean, median, standard deviation, quartiles, min, max) of
- number of exacerbations per patient since IPF diagnosis during observation period (as defined in “Computed variables” chapter)
- number of exacerbations per patient since IPF diagnosis during observation period stratified by exacerbation severity
[F08_EXACERBATIONS.Ex_exacer_1-10_Severity]

Descriptives will be calculated out of the number of patients evaluable at enrollment.
31. Specialist and general practitioner outpatient visits

The table will provide:

- Distribution of patients with at least one specialist or general practitioner outpatient visit for IPF, IPF exacerbations or IPF-related adverse events from diagnosis to the end of observation period [F20_Resource_CONS.Specialist, RES_other_Specialist].
- Distribution of patients by type of specialist outpatient visits from diagnosis to the end of observation period. One patient could perform more than one type of specialist outpatient visit. A patient who performed the same type of visit more than once will count one.
- Descriptive statistics (mean, median, standard deviation, quartiles, min, max) of the number of specialist outpatient visits per patient (overall and by visit type) from diagnosis to the end of observation period.

MOD 1037.B Rev 01 del 15-11-2012 modified on 20th January 2017
• Descriptive statistics (mean, median, standard deviation, quartiles, min, max) of the number of GP visits for IPF, IPF exacerbations or IPF related adverse events per patient [F20_RESOURCE_CONS.RES_GP_Visit_YN_Num] from diagnosis to the end of observation period. Analyses will be computed out of the total number of patients evaluable at enrollment.

Table 32. Patients who performed laboratory tests
The table will provide
• Distribution of patients with at least one laboratory test for IPF, IPF exacerbations or IPF related adverse events from diagnosis to the end of observation period [F20_RESOURCE_CONS.RES_LAB_TEST_YN]
Analyses will be computed out of the total number of patients evaluable at enrollment.

Table 33. Laboratory tests: number and type
The table will provide
• Descriptive statistics (mean, median, standard deviation, quartiles, min, max) of the number of laboratory tests per patient [F20 RESOURCE CONS.RES_LAB_matrix_1_num- RES_LAB_matrix_10_num] from diagnosis to the end of observation period, overall and stratified by type of test/examination.
Analyses will be computed out of the total number of patients evaluable at enrollment.

4.9 Ongoing therapies for IPF

Table 34. IPF treatments ongoing at enrollment
The table will provide:
• Frequency distribution of patients with at least one IPF pharmacological treatment ongoing at baseline [F09_THERAPY_IPF.THER_Pharma_YN].
• Frequency distribution of patients with at least one IPF non pharmacological treatment ongoing at baseline [F09_THERAPY_IPF.THER_non_parma_YN].
• Frequency distribution of patients listed for lung transplantation at enrollment [F09_THERAPY_IPF.THER_transplant_YN]. stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs).
Percentages will be computed out of the total number of patients evaluable at enrollment.

Table 35. IPF treatments ongoing at 3-month follow up
The table will provide:
• Frequency distribution of patients with at least one IPF pharmacological treatment ongoing at 3-month follow up.
• Frequency distribution of patients with at least one IPF non pharmacological treatment ongoing at 3-month follow up.
• Frequency distribution of patients listed for lung transplantation at 3-month follow up [F09_THERAPY_IPF.THER_transplant_fup_YN]. stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs).
Percentages will be computed out of the total number of patients who performed the 3-month follow up.

Table 36. IPF treatments ongoing at 6-month follow up
The table will provide:
• Frequency distribution of patients with at least one IPF pharmacological treatment ongoing at 6-month follow up.
• Frequency distribution of patients with at least one IPF non pharmacological treatment ongoing at 6-month follow up.
• Frequency distribution of patients listed for lung transplantation at 6-month follow up [F09_THERAPY_IPF.THER_transplant_fup_YN]. stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs).
Percentages will be computed out of the total number of patients who performed the 6-month follow up.

Table 37. IPF treatments ongoing at 12-month follow up
The table will provide:
• Frequency distribution of patients with at least one IPF pharmacological treatment ongoing at 12-month follow up.
• Frequency distribution of patients with at least one IPF non pharmacological treatment ongoing at 12-month follow up.
• Frequency distribution of patients listed for lung transplantation at 12-month follow up [F09_THERAPY_IPF.THER_transplant_fup_YN]. stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs).
Percentages will be computed out of the total number of patients who performed the 12-month follow up.

4.10 Ongoing pharmacological therapies for IPF
Table 38. Distribution of patients according to IPF pharmacological treatments ongoing at enrollment
The table will provide the frequency distribution of IPF pharmacological treatments (actives) ongoing at enrollment (see ‘Computed variables’ chapter) stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs). A patient could receive more than one active. Percentages will be computed out of the total number of patients evaluable at enrollment.

Table 39. Distribution of patients according to IPF pharmacological treatments ongoing at 3-month follow up
The table will provide the frequency distribution of IPF pharmacological treatments (actives) ongoing at 3-month follow up (see ‘Computed variables’ chapter) stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs). A patient could receive more than one active. Percentages will be computed out of the total number of patients who performed the 3-month follow up.

Table 40. Distribution of patients according to IPF pharmacological treatments ongoing at 6-month follow-up visit
The table will provide the frequency distribution of IPF pharmacological treatments (actives) ongoing at 6-month follow up (see ‘Computed variables’ chapter) stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs). A patient could receive more than one active. Percentages will be computed out of the total number of patients who performed the 6-month follow up.

Table 41. Distribution of patients according to IPF pharmacological treatments ongoing at 12-month follow-up visit
The table will provide the frequency distribution of IPF pharmacological treatments (actives) ongoing at 12-month follow up (see ‘Computed variables’ chapter) stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs). A patient could receive more than one active. Percentages will be computed out of the total number of patients who performed the 12-month follow up.

Table 42. IPF pharmacological treatments from diagnosis to the end of observation period – Dosage regimen
The table will consider all the pharmacological treatments assumed by the patients for IPF, IPF-exacerbations or IPF-related AEs from diagnosis to the end of observation period. It will provide:
Descriptive statistics (mean, median, standard deviation, quartiles, min, max) of the IPF pharmacological treatment dosage per administration by Drug, Unit of administration, frequency of administration [F23_IPF_PHARMACOLOGICAL THERAPY.DRUG, UNIT_3,FREQ_ADMN] and duration of therapy (number of days).
Two separate tables will be provided: one for IPF pharmacological treatments ongoing at enrollment having/not having fixed-dose formulation [F23_IPF_PHARMACOLOGICAL THERAPY.DOSE_2].
The patients evaluable at enrollment will be considered.

Table 43. Time between diagnosis and start of therapy for IPF
The table will provide the main descriptive statistics (mean, median, standard deviation, quartiles, min, max) of the time between diagnosis and start of therapy for IPF (weeks).
First therapy for IPF assumed by evaluable patients will be considered. Only therapies for IPF will be considered.

4.11 Pharmacological therapies for IPF and exacerbations
Listing 44. Patients with exacerbations during observational period and therapy for IPF
A listing of patients with at least one exacerbation during observational period will be shown. The therapy ongoing before the exacerbation and the therapy ongoing after the exacerbation will be shown; in case of no therapy, this will be indicated in the listing.
In case of more than one exacerbation all the above information (about therapy before and after the exacerbation) will be shown referring to each exacerbations.

4.12 Ongoing non pharmacological therapies for IPF
Table 45. IPF non pharmacological therapy ongoing at enrollment
The table will provide the frequency distribution of IPF non pharmacological therapies (long-term oxygen therapy, cardiopulmonary exercise training or psychological support) ongoing at enrollment (see ‘Computed variables’ chapter) stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs).
Percentages will be computed out of the total number of patients evaluable at enrollment.

Table 46. Distribution of patients according to IPF non pharmacological therapy ongoing at 3-month follow up
The table will provide the frequency distribution of IPF non pharmacological therapies (long-term oxygen therapy, cardiopulmonary exercise training or psychological support) ongoing at 3-month follow-up visit (see ‘Computed variables’ chapter) stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs).
Percentages will be computed out of the total number of patients who performed the 3-month follow up.
Table 47. Distribution of patients according to IPF non pharmacological therapy ongoing at 6-month follow-up visit
The table will provide the frequency distribution of IPF non pharmacological therapies (long-term oxygen therapy, cardiopulmonary exercise training or psychological support) ongoing at 6-month follow-up visit (see ‘Computed variables’ chapter) stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs). Percentages will be computed out of the total number of patients who performed the 6-month follow up.

Table 48. Distribution of patients according to IPF non pharmacological therapy ongoing at 12-month follow-up visit
The table will provide the frequency distribution of IPF non pharmacological therapies (long-term oxygen therapy, cardiopulmonary exercise training or psychological support) ongoing at 12-month follow-up visit (see ‘Computed variables’ chapter) stratified by type of therapy (therapy for IPF, IPF-exacerbations or IPF-related AEs). Percentages will be computed out of the total number of patients who performed the 12-month follow up.

Table 49. IPF non pharmacological therapy from diagnosis to the end of observation period – Number of sessions of cardiopulmonary exercise training or psychological support
It will provide the descriptive statistics (mean, median, standard deviation, quartiles, min, max) of the total number of sessions of cardiopulmonary exercise training or psychological support performed from diagnosis to the end of observation period [F24_NON_PHARMACOLOGICAL_THERAPY.N_SESSIONS] by therapy [F24_NON_PHARMACOLOGICAL_THERAPY.THERAPY]. The patients evaluable at enrollment will be considered.

Table 50. Long term Oxygen therapy from diagnosis to the end of observation period – Dosage regimen
The table will consider all the long-term oxygen therapies assumed by the patients for IPF, IPF-exacerbations or IPF_related AEs from diagnosis to the end of observation period. It will provide the descriptive statistics (mean, median, standard deviation, quartiles, min, max) of the flow (L/min) [F24_NON_PHARMACOLOGICAL_THERAPY.FLOW] by Drug [F24_NON_PHARMACOLOGICAL_THERAPY.DRUG], Hours per day [F24_NON_PHARMACOLOGICAL_THERAPY.HOURS] and duration of therapy (number of days). The patients evaluable at enrollment will be considered.

4.14 AEs and ADRs between diagnosis and end of observation

Table 52. Patients with AEs and ADRs between diagnosis and end of observation
The table will provide the absolute and relative frequency of the patients with at least one adverse events between diagnosis and end of observation. The total number of evaluable patients at enrollment will be considered.

Listing 53. AEs and ADRs between diagnosis and end of observation
The table will provide the distribution of every AE or ADR, occurred between diagnosis and end of observation by serious AE, seriousness category and causal relationship with Nintedanib. The total number of evaluable patients at enrollment will be considered.

4.15 Appendix
Table A3. Methods of diagnosis (by HRCT findings)
The table will provide the distribution of methods of evaluable patients according to methods of diagnosis crosstabulated by HRCT finding compatible with current ATS/ERS criteria.
The table will be provided considering patients evaluable at enrollment.

Table A4. IPF treatments ongoing at enrollment (Patients with IPF symptoms at baseline and no symptoms at 3-month follow up)
The table will provide the frequency distribution of patients with at least one pharmacological therapy for IPF ongoing at enrollment.
The patients with IPF symptoms at baseline and no symptoms at 3-month follow up will be considered.
The table will be provided at V3 and V5.

Table A5. Distribution of patients according to IPF pharmacological treatments ongoing at enrollment (Patients with IPF symptoms at baseline and no symptoms at 3-month follow up)
The table will provide the frequency distribution of patients according to IPF pharmacological treatments ongoing at enrollment.
The patients with IPF symptoms at baseline and no symptoms at 3-month follow up will be considered.
The table will be provided at V3 and V5.

Table A6. IPF treatments ongoing at 3-month follow up (Patients with IPF symptoms at baseline and no symptoms at 3-month follow up)
The table will provide the frequency distribution of patients with at least one pharmacological therapy for IPF ongoing at 3-month follow up.
The patients with IPF symptoms at baseline and no symptoms at 3-month follow up.
The table will be provided at V3 and V5.

Table A7. Distribution of patients according to IPF pharmacological treatments ongoing at 3-month follow up (Patients with IPF symptoms at baseline and no symptoms at 3-month follow up)
The table will provide the frequency distribution of patients according to IPF pharmacological treatments ongoing at 3-month follow up.
The patients with IPF symptoms at baseline and no symptoms at 3-month follow up will be considered.
The table will be provided at V3 and V5.